Search Foundayo (type in keywords)

Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Foundayo ^™ (orforglipron) tablet

0.8 mg / 2.5 mg / 5.5 mg / 9 mg / 14.5 mg / 17.2 mg

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

What is the incidence of hypersensitivity reactions with Foundayo™ (orforglipron)?

In ATTAIN-1 and -2, 1 (<1%) orforglipron-treated participant reported a hypersensitivity reaction. Orforglipron is contraindicated in people with known serious hypersensitivity to orforglipron or any of the excipients in orforglipron.

Export Document

See important safety information, including boxed warning, in the attached prescribing information.

Orforglipron is contraindicated in patients with known serious hypersensitivity to orforglipron or any of the excipients in orforglipron.¹

Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with glucagon-like peptide-1 receptor agonists.¹

Were Hypersensitivity Events Reported in Orforglipron Phase 3 Weight Management Studies?

ATTAIN-1 and ATTAIN-2 were randomized, double-blind, placebo-controlled trials evaluating the efficacy and safety of orforglipron in adults with obesity or overweight. ATTAIN-1 enrolled participants without type 2 diabetes (T2D) and ATTAIN-2 enrolled participants with T2D.^2,3

These studies compared an investigational orforglipron capsule formulation with placebo during 72 weeks, plus a 2-week off-drug follow-up.^2,3

This response presents safety data from the investigational orforglipron capsule formulation (1 mg, 3 mg, 6 mg, 12 mg, 24 mg, and 36 mg) shown as equivalent doses of once daily orforglipron tablets (0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, and 17.2 mg) approved in the United States.^1-3

In the ATTAIN-1 and ATTAIN-2 clinical studies, which enrolled more than 4000 participants across 13 counties, there was 1 orforglipron-treated participant who reported a hypersensitivity reaction.^2,3

Adverse events of hypersensitivity reported in ATTAIN-1 and ATTAIN-2 are presented in Table 1.

Table 1. Adverse Events of Hypersensitivity in ATTAIN-1 and ATTAIN-2^1-3

Adverse event^a	OFG 5.5 mg	OFG 9 mg	OFG 17.2 mg	PBO	Total
ATTAIN-1	N=723	N=724	N=728	N=948	N=3123
Hypersensitivity^b	0 (0)	0 (0)	0 (0)	1 (1)	1 (<0.1)
ATTAIN-2	N=328	N=331	N=321	N=628	N=1608
Hypersensitivity^b	1 (0.3)	0 (0)	0 (0)	0 (0)	1 (0·1)

Abbreviations: OFG = orforglipron; PBO = placebo.
^a Data are shown as n (%).
^b Includes only events that were classified as severe or serious adverse events.

How to Manage Hypersensitivity Reactions in Patients Taking Orforglipron?

The ATTAIN-1 and ATTAIN-2 protocols did not provide specific guidance about the management of hypersensitivity reactions. During the trials, investigators used local guidelines to manage systemic hypersensitivity reactions or participants were permanently discontinued from study intervention.^2,4

Eli Lilly and Company cannot provide treatment recommendations on how to manage hypersensitivity reactions in patients using orforglipron. In formulating an assessment and approach, the health care practitioner may consider

the patient’s prior medical history and concomitant medications, and
other individual factors.

The health care practitioner should consider potential risks and benefits of treatment options and monitor appropriately.

Enclosed Prescribing Information

FOUNDAYO™ (orforglipron) tablets, for oral use, Lilly

References

The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).

Foundayo [package insert]. Indianapolis, IN: Eli Lilly and Company; 2026.
Wharton S, Aronne LJ, Stefanski A, et al; ATTAIN-1 Trial Investigators. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. 2025;393(18):1796-1806. https://doi.org/10.1056/NEJMoa2511774
Horn DB, Ryan DH, Giljanovic Kis S, et al; ATTAIN-2 Trial Investigators. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. Lancet. 2025;406(10522):2927-2944. https://doi.org/10.1016/S0140-6736(25)02165-8.
Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Date of Last Review: April 03, 2026

Are you satisfied with this content?

Foundayo ™ (orforglipron) tablet